Background. The purpose of this study was to examine the prognostic impact of occult disease after extrapleural pneumonectomy for malignant mesothelioma.
M
alignant pleural mesothelioma is a rare, highly aggressive tumour with a very poor prognosis [1] [2] [3] . Despite extensive surgical removal provided by extrapleural pneumonectomy, patients relapsed rapidly. Therefore, most treatment regimens have focused on radiation therapy, chemotherapy and immunotherapy multimodality treatment [4] , or neoadjuvant chemotherapy [5] .
According to these observations it is conceivable that some residual tumor may persist in spite of aggressive and extended surgery. In malignant pleural mesothelioma, the main sites of recurrence are represented by either local or mediastinal intrathoracic seeding [6] . These tumoral nests are likely located in proximity of resection margins or in mediastinal nodes not adequately assessed at the time of thoracotomy. Indeed, positive resection margins and mediastinal lymph node metastases have been identified as poor prognostic factors in many published series [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . However, some patients experience a poor outcome despite a histologically proven complete surgical resection. We have recently investigated the role of occult residual or micrometastases in lung neoplasms detected by immunohistochemistry, and we found that their evidence may justify unpredictable recurrence patterns [13] . Therefore, we have extended our observations to malignant pleural mesothelioma.
The aim of the present study was to examine, in a group of patients undergoing extrapleural pneumonectomy, the prognostic impact of occult disease in resection margins and mediastinal lymph nodes identified after immunohistochemical staining with anticalretinin and antimesothelin monoclonal antibodies [14] . The role of preoperative cervical mediastinoscopy in patient selection was also investigated. Permission for this retrospective study and authorization for tissue samples reanalysis was obtained from the institutional review boards of each institution where the operations were performed.
Patients and Methods

Patients
Patients considered eligible for extrapleural pneumonectomy were those with a confirmed preoperative diagnosis of malignant pleural mesothelioma at stage T1 through T3 according to the International Mesothelioma Interest Group [8] , with a Karnofsky index equal to or greater than 90%, and without major organ dysfunction. Physiologic reasons for inoperability were a predicted postoperative forced expiratory volume in 1 second less than 40% of the predicted value or less than 1 L and evidence of contralateral hypoperfused lung (less than 55% of the right or 45% on the left). Other criteria of exclusion were room air arterial partial pressure of carbon dioxide greater than 45 mm Hg or arterial partial pressure of oxygen less than 65 mm Hg, an estimated cardiac ejection fraction less than 0.45, or right ventricular dilatation.
All patients had undergone computed tomographic scan of the thorax and upper abdomen and contrast-enhanced magnetic resonance imaging. This study group population was gathered before the arrival of a positron emission tomography scanner. Resectability was defined by tumor confined to one hemithorax, with the absence of mediastinal organ or full-thickness pericardial or myocardial involvement, absence of diffuse or multifocal chest wall disease, transdiaphragmatic extension, or spread directly into the spine, hence excluding stage T4 disease. Preoperative cervical mediastinoscopy was performed whenever computed tomographic scan evidenced enlarged upper mediastinal lymph nodes (a maximum diameter greater than 15 mm). The evidence of positive mediastinal lymph nodes was considered an absolute exclusion criterion for extrapleural pneumonectomy.
Surgical Technique
Briefly, extrapleural pneumonectomy was performed through an extended posterolateral thoracotomy, in most cases through the sixth intercostal space with a counterincision in the eighth one. The procedure included en bloc excision of the lung, pleura, hemipericardium, and hemidiaphragm. The pleura was bluntly dissected along the extrapleural plane, saving the endothoracic fascia whenever possible. In sites of localized infiltration and of previous biopsies, the chest wall was excised en bloc with the specimen or subsequently resected. The mediastinal pleura was dissected from the apex toward the hilum. The pericardium was opened and widely excised on both the anterior and posterior sides. Vessels and bronchus were approached as in any intrapericardial pneumonectomy and sutured using stapling devices. The diaphragm was completely separated from the peritoneum and resected at its insertion to the chest wall. Incidental peritoneal tears were sutured. 
Conventional Pathologic Examination
During the immediate postoperative period, each specimen was routinely processed as follows. First, the surgeon conducted a gross examination immediately after the procedure, indicating potential areas of incomplete resection. Second, the pathologist macroscopically evaluated the specimen to determine any areas with obvious evidence of residual tumor, paying special attention to the sites indicated by the surgeon. Third, each suspect area was separately embedded in wax and stained for microscopic examination with traditional hematoxylin and eosin. In addition, approximately 20 sections were randomly taken from each specimen in correspondence of selected pleural sites: anterior, lateral, and posterior costophrenic sinus, pericardiophrenic sinus, anterior and posterior mediastinal pleura, and vertebral groove. The bronchial stump, pericardium, and diaphragm were routinely examined for microscopic margins. A positive margin was used to target direct adjuvant radiation treatment. Each lymph node was embedded in wax and sections were stained with hematoxylin and eosin for microscopic examination to determine the presence of metastatic tumor. All embedded samples were stored and were available for future reanalysis.
Adjuvant Therapy
Adjuvant chemotherapy and radiotherapy always followed the surgical procedure. The chemotherapy regimen usually consisted of four to six cycles of cisplatin (100 mg/m 2 ) given at day 15, and etoposide (120 mg/m 2 ) administered on days 1, 2, and 3 or, since 1996, gemcitabine (1 g/m 2 ) administered on days 1, 8, and 15. Cisplatin was infused for 1 hour after intravenous hyperhydration with 2,000 mL of saline solution plus potassium chloride. Etoposide or gemcitabine were administered as a 30-minute intravenous infusion diluted with 250 mL of saline solution. Treatment was discontinued in case of disease progression or intolerable toxicity. Functional assessment (ie, complete and differential blood cell counts, urea nitrogen, creatinine clearance, bilirubin, and liver enzymes) was repeated before each cycle. Dose reduction and delay in therapy were established according to hematologic and nonhematologic toxicity, scored according to the common toxicity criteria (from 0 ϭ no toxicity to 4 ϭ maximal toxicity) [11] . Chemotherapy was started between 4 and 10 weeks after extrapleural pneu-monectomy depending on the postoperative recovery. Treatment was repeated every 4 weeks.
Radiation therapy usually followed the cycles of chemotherapy. External beam radiotherapy was delivered with an energy ranging from 4 to 15 MV. The total radiation doses to the hemithorax and mediastinum were usually 30 and 40 Gy, respectively, divided into 1.5 Gy fractions. A boost dose (14 Gy in 2 Gy fractions) was always delivered to areas with gross residual disease or positive resection margins, and to metastatic lymph nodes.
Clinical Follow-Up
Whenever possible, clinical outcome was directly assessed during a dedicated session of follow-up outpatient clinic. Alternatively, basic information was retrieved by medical records or general practitioner or patients' interviews by telephone call. Cross-sectional contact for all surviving patients was performed on September 2006. Because clinical symptoms and radiographic studies available during the beginning of the study period were not sensitive enough to accurately diagnose early recurrence, the disease-free interval was not evaluated. Therefore, survival was the major end point of this study. The survival duration was measured from the date of extrapleural pneumonectomy until the date of the patient's last follow-up contact or death.
Immunohistochemical Studies
All the included specimens for resection margin assessment and all extrapleural nodes available from these patients were reviewed after immunohistochemical staining with anticalretinin and antimesothelin monoclonal antibodies. Immunostaining was performed on formalin-fixed, paraffin-embedded tissue sections using the avidin-biotin-peroxidase method. Appropriate sections were cut 4 m thick and air-dried overnight at 37°C. Sections were then stripped of paraffin with xylene and rehydrated in titrated ethanol series. Endogenous peroxidase activity was blocked with a 10-minute immersion in 0.3% hydrogen peroxide in methanol, followed by a single wash in phosphate-buffered saline solution (pH 7.4). The primary antibodies used in each case were the following: anticalretinin antibody (Swant, Bellinzona, Switzerland; 1:1,500 dilution) and the mesothelin 5B2 monoclonal antibody (Novocastra Laboratories, Newcastle-upon-Tyne, UK; 1:20 dilution). The immunostaining was developed using 3,3=-diaminobenzidine as the chromogen. Negative control sections included nonimmune mouse or rabbit serum as a substitute for the primary antibody. Immunoreactivity was scored as negative (no immunostaining) or positive by an experienced pathologist (A.B.). Cases were considered positive whenever both antigens were detected in at least five cells demonstrating positive immunostaining and morphology compatible with mesothelioma. .0001; Fig 1) . No significant superiority between antigens was detected (data not shown). The median postoperative survival of patients with microinfiltration of resection margins was 9 months (95% confidence interval, 7.5 to 10.4), significantly less than those without residual disease, which was 22 months (95% confidence interval, 20.6 to 31.0). Interestingly, the probability of discovering occult metastases was not correlated with a higher T stage ( (Table 2) .
Statistical Analysis
Results
Histologic
Microscopic N disease was discovered in 5 patients. All these patients presented at least one positive station located in the upper mediastinum that could have been reached by cervical mediastinoscopy (Table 3) . Interestingly, in 2 of these patients, the lymph nodes harvested during cervical mediastinoscopy were negative at conventional staining but revealed positivity after immunohistochemical reassessment. The presence of metastases was not correlated with lymph node size: negative node median diameter was not significantly different from the positive ones (Table 3 ). The survival curve according to the immunohistochemical N disease reassessment was more significant (p ϭ 0.001; Fig 2) . The median postoperative survival of patients with lymph node metastases was 8 months (95% confidence interval, 6.3 to 9.4) significantly less than those without node metastases, which was 21 months (95% confidence interval, 19.6 to 29.0).
Combining the two variables reassessed by immunohistochemistry, we discovered 5 new patients with occult disease, 2 patients with positive resection margin only, 1 with positive node only, and 2 with both. The other 2 patients with newly discovered resection margin had positive lymph nodes at conventional staining, and the remaining 2 with nodal micrometastases had already yielded positive results at resection margin evaluation. In this way the significance reached a very high level in overall survival (p Ͻ 0.0001; Table 1 ). Figure 3 showed that patients found positive (margin plus nodes) only at immunostaining have a similar survival to those positive at conventional technique.
At Cox regression analysis, the combined resection margin and nodal status reassessed by immunohistochemistry was selected as the most significant prognosticator (p Ͻ 0.0001; odds ratio, 5.4; 95% confidence interval, 3 to 15).
Comment
Extrapleural pneumonectomy remains a cornerstone of the multimodality treatment of malignant pleural mesothelioma. This is valid for the classic trimodality approach pioneered by Sugarbaker and colleagues [15] , for the neoadjuvant chemotherapy strategy proposed by Weder and associates [5] , and for the intensitymodulated adjuvant radiotherapy established by Rice and coworkers [16] . Nonetheless, results achieved are not yet satisfying, and median survival is quite low. In the On the basis of recent progress in immunohistochemical techniques for detection of occult neoplastic disease and analogous experiences in other neoplasms [13] , we decided to reassess infiltration of resection margins and lymph node metastasis. Indications from the literature [14] have led us to use monoclonal antibodies against specific mesothelioma markers such as calretinin and mesothelin. The resection margin evaluation of an extrapleural pneumonectomy per se represents a great challenge. In fact, the surface to be examined is so extended that even the most accurate pathologic examination cannot be considered totally reliable. According to Sugarbaker and colleagues [4] , we have already adopted a compromise solution by selecting areas with obvious macroscopic infiltration, with a high infiltration risk (ie, bronchus, pericardium, diaphragm), and some specific areas of the parietal pleura for classic microscopic studies. The same paraffin-embedded specimens were reassessed with immunohistochemistry for the present study.
In our series, the traditional histologic examination already evidenced the positive resection margin and the nodal status, together with the histologic type, as the sole significant prognostic factors. Nevertheless, the reassessment with immunohistochemistry contributed to demonstrate the presence of occult disease in 5 new patients, which represented almost 15% of our study group. The survival curve, according to the new reassessment, was more significant (p Ͻ 0.0001). Interestingly, we found that the probability of discovering occult metastases was not correlated with a higher T stage. This contradicts the diffuse opinion that a more elevated T stage may increase the risk of leaving tumoral cells. We tried to explain this apparent paradox by the fact that a lower T stage may favor a less full-thickness resection, increasing the possibility of leaving tumor areas. Indeed, the anterior or posterior costophrenic sinus, which is the more difficult site to access by lateral thoracotomy, was the most frequent site of occult residual disease.
Extrapleural lymph node metastases are detectable from 28% to 52% of all the patients undergoing extended surgery [4, 6, 11, 12, 15] and are related to a significantly poorer prognosis after radical resection [4, 6, 12, 17]. In our series, they represented 15%, increasing to 34% when using immunohistochemical staining.
In accordance with Prenzel and coworkers [18] , we also found that the long-axis diameter of lymph nodes containing metastatic tumor is not significantly different from those free of tumor. Because lymph node size is not significantly different when involved by metastatic mesothelioma, preoperative imaging using size criteria will be unreliable for staging extrapleural lymph node metastasis, and this justifies the low results in patient selection achieved by positron emission tomography [19, 20] . Thus, we reaffirmed the role of preoperative cervical mediastinoscopy in patient candidates to extended radical resection in malignant pleural mesothelioma. Most positive mediastinal lymph nodes are accessible to mediastinoscopy [6, 9, 21]. On the other hand, the probability of positive nodes not accessible to mediastinoscopy is quite low [4, 22] . In our series, in all patients metastatic lymph nodes were located in the upper mediastinum. Thus, they could all have potentially been accessible to mediastinoscopy. We also found that the use of immunohistochemical staining can improve the diagnostic accuracy of the test.
We acknowledge some limitations in our study. The main limitation relies on its retrospective nature and the relatively limited sample size. However, it must be noted that immunohistochemistry reassessment of all specimens was achieved in a limited period with the same technique and by the same pathologist. Moreover, although the study covers a period of 20 years and multimodality treatments are slightly different owing to the long time span, the surgical procedure was performed according to the same criteria and by the same surgeon. Another limitation can be represented by the method in assessing resection margins, but this is the same method used in other qualified institutions.
In conclusion, we affirm that extrapleural pneumonectomy can be performed with an acceptable low mortality rate in multimodality therapy of selected patients with malignant pleural mesothelioma. The detection of occult disease in resection margins and N disease may allow a more accurate prediction of survival, thus influencing surveillance and therapeutic strategies. Because N disease is a clear contraindication to mesothelioma resection, all patients considered for potential radical resection should undergo preoperative routine cervical mediastinoscopy and all specimens should be processed with immunohistochemical techniques.
